Tvaster Genkalp, a company specializing in molecular diagnostics, announced $1.25 million in fresh capital from lead investor Ideaspring Capital and others, according to reporting by eHealth Network. The pre-Series A round will enable the commercialization and expansion of its Episcreen Liver diagnostic test product.
Working with advanced epigenetic screening technologies, Tvaster Genkalp develops non-invasive genetic solutions designed to make cancer detection more accurate. Its Episcreen Liver offering is a liquid biopsy test for early liver cancer detection.
Alongside expanding its liver cancer screening product across India, Tvaster Genkalp plans to fuel research and development in precision oncology and molecular diagnostics, the eHealth Network article mentioned. The company is furthering its oncology diagnostics pipeline with Episcreen Bile, a test for a type of bile duct cancer, and Episcreen HBResist, a chemotherapy resistance test for pediatric cancer.
